Skip to content
Open access

The GPX3‐VCAM1 Axis Gates Pro‐Fibrotic Tubule Cell Fate in Hyperuricemic Nephropathy

Sep 2026 · Advancement of science · 0 citations · 48 references
Medicine

TL;DR

A genetically defined, multi‐hit mouse model that recapitulates the sustained hyperuricemia, metabolic dysregulation, and progressive fibrosis of human disease is established and glutathione peroxidase 3 (GPX3) is identified as a master regulator restraining precursor cell differentiation into Profib PT cells.

Abstract

ABSTRACT Hyperuricemia is a major driver of chronic kidney disease, yet the underlying intrarenal mechanisms remain unclear. Here, we establish a genetically defined, multi‐hit mouse model that recapitulates the sustained hyperuricemia, metabolic dysregulation, and progressive fibrosis of human disease. Using this model, we demonstrate that soluble uric acid activates the renal NLRP3 inflammasome and that its inhibition attenuates kidney injury. Single‐nucleus RNA sequencing revealed a distinct pro‐inflammatory and pro‐fibrotic proximal tubule cell population (Profib PT) marked by high VCAM1 expression, which is conserved in human kidney disease. Direct VCAM1 neutralization with antibodies attenuated renal fibrosis, validating its functional role. Mechanistically, we identify glutathione peroxidase 3 (GPX3) as a master regulator restraining precursor cell differentiation into Profib PT cells. GPX3 expression is suppressed in hyperuricemia, licensing this pathogenic transition; conversely, dietary selenium supplementation restored GPX3 activity, blocked Profib PT differentiation and VCAM1‐dependent macrophage adhesion, and ameliorated renal fibrosis. Our findings define the GPX3‐VCAM1 axis as a central regulatory node in hyperuricemic nephropathy and identify nutritional selenium repletion as a novel therapeutic strategy to intercept fibrosis.

Read PDF

Similar papers

Sep 2026

A Non-canonical role of phloretin in renal protection: Targeting WNT2B downregulation to prime PINK1/ PARKIN-dependent mitophagy and attenuate renal fibrosis.

Renal fibrosis, the common pathological endpoint of diverse kidney injuries, drives the progression to end-stage kidney disease. Its rising prevalence, mirroring the global chronic kidney disease burden, starkly contrasts with the unmet need for safe and effective therapies. Fibrogenesis is centrally driven by transfor...

Xue Wu, Yong-Hui Dong, Jia Li et al. · 0 citations
Open access Aug 2026

Genetic and pharmaceutical targeting of Suv39h1 ameliorates renal fibrosis by unlocking CXCL10 transcription.

A critical role for the lysine methyltransferase Suv39h1 in regulating fibroblast-myofibroblast transition (FMyT) and renal fibrosis is identified and Suv39h1-mediated regulation as a previously unrecognized facet of renal fibrogenesis is identified.

Xiao-Yan Wu, Ya-Jun Luo, Caiyi Wu et al. · 0 citations
Sep 2026

Complanatuside Ameliorates Renal Injury and Fibrosis in Chronic Kidney Disease by Inhibiting Tubular Cell Apoptosis via Activation of KLK1/BDKRB2.

It is found that CPT binds to KLK1, activates its expression, reduces PTEC apoptosis, and thereby attenuates renal fibrosis, and reveals that CPT binds to KLK1, promotes BDKRB2 expression, thereby reducing PTEC apoptosis and improving renal fibrosis.

Jing Gao, Rui-Zhi Tan, K. Deng et al. · 0 citations
Open access Sep 2026

Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses

Chronic kidney disease (CKD) is partly driven by excessive innate immune activation, which contributes to progressive renal injury and fibrosis. Disulfiram (DSF), an approved treatment for alcohol dependence, has recently emerged as an inhibitor of innate immune responses such as pyroptosis. In this study, we investiga...

Saori Kin, Yuji Oe, Shun Ishigaki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.